Screener
Zymeworks ZYME Business Segments
| Q2 '26 | Q1 '26 | Q2 '25 | ||
|---|---|---|---|---|
| R&D by Product | ||||
| Expense for other preclinical and research programs | $4.19M-32.1% | $7.26M+19.6% | $6.17M— | |
| Zanidatamab | $2.18M+45.3% | $623K-55.6% | $1.5M— | |
| ZW171 | -$458K-114% | $1.15M-48.4% | $3.32M— | |
| ZW191 | $3.13M+13.1% | $3.03M+77.7% | $2.76M— | |
| ZW220 | -$152K-146% | $97K-95.6% | $327K— | |
| ZW251 | $3.21M+37.0% | $1.91M-51.7% | $2.34M— |
FAQ
- How does Zymeworks break its business down?
- Zymeworks (ZYME) reports r&d by product across 6 parts — Expense for other preclinical and research programs, Zanidatamab, ZW171, ZW191 and ZW220. Each is extracted from the segment footnotes and tracked over time.
- Where does Zymeworks's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Zymeworks's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
